Hertz contact intravascular lithotripsy for calcified coronary artery disease: the PINNACLE-I trial - PubMed
4 days ago
- #intravascular lithotripsy
- #coronary artery disease
- #PINNACLE-I trial
- The PINNACLE-I trial evaluated the LithiX lithotripsy device using Hertz contact (HC) mechanism for treating calcified coronary artery disease.
- HC-IVL was found to be safe and effective, achieving calcium fractures in 90.6% of lesions with a mean fracture depth of 0.81±0.33 mm.
- The primary endpoint of <50% residual stenosis without in-hospital major adverse cardiovascular events (MACE) was achieved in 98.3% of cases.
- 30-day MACE rate was 1.7%, with no cardiovascular deaths, stent thromboses, or device-related events up to 6 months.
- Stent expansion at the minimum stent area site was 96.7±25.5%, indicating optimal stent placement.
- The study included a diverse range of calcium morphologies, demonstrating the device's broad applicability.